242 related articles for article (PubMed ID: 32418256)
41. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
42. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.
Gasoyan H; Anwer F; Casacchia NJ; Kovach JD; Valent J; Wang M; Halpern MT; Rothberg MB
JCO Oncol Pract; 2024 May; 20(5):699-707. PubMed ID: 38354331
[TBL] [Abstract][Full Text] [Related]
43. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Usmani S; Ahmadi T; Ng Y; Lam A; Desai A; Potluri R; Mehra M
Oncologist; 2016 Nov; 21(11):1355-1361. PubMed ID: 27486203
[TBL] [Abstract][Full Text] [Related]
44. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.
Jurczyszyn A; Davila J; Kortüm KM; Jayabalan DS; Vij R; Fiala M; Milunovic V; Chim CS; Wiśniewska-Piąty K; Waszczuk-Gajda A; Crusoe E; Hajek R; Robak P; Raźny M; Zawirska D; Bittrich M; Nahi H; Liu J; Castillo JJ; Vesole DH
Leuk Lymphoma; 2019 Feb; 60(2):471-476. PubMed ID: 30033832
[TBL] [Abstract][Full Text] [Related]
45. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
46. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
47. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
[TBL] [Abstract][Full Text] [Related]
49. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
[TBL] [Abstract][Full Text] [Related]
50. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
51. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
[TBL] [Abstract][Full Text] [Related]
52. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Brown J; Liepa AM; Bapat B; Madhwani S; Lorenzen S; García-Foncillas J; Candrilli SD; Kaye JA
Eur J Cancer Care (Engl); 2020 Mar; 29(2):e13213. PubMed ID: 31883156
[TBL] [Abstract][Full Text] [Related]
53. The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.
Yang Y; Li J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Aihemaiti X; Chen F; Xu T; Xu J; Liu P
Cancer Med; 2023 Apr; 12(8):9604-9614. PubMed ID: 36807775
[TBL] [Abstract][Full Text] [Related]
54. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis.
Al Saleh AS; Visram A; Parmar H; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Go RS; Gonsalves WI; Kourelis TV; Hayman SR; Kapoor P; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Leuk Lymphoma; 2021 Dec; 62(12):3011-3018. PubMed ID: 34263694
[TBL] [Abstract][Full Text] [Related]
55. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
56. Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: A retrospective cohort study.
Chen YL; Liu YC; Wu CH; Yeh CM; Chiu HI; Lee GY; Lee YT; Hsu P; Lin TW; Gau JP; Hsiao LT; Chiou TJ; Liu JH; Liu CJ
Hematol Oncol; 2018 Apr; 36(2):407-415. PubMed ID: 29105945
[TBL] [Abstract][Full Text] [Related]
57. Sequencing of myeloma therapy: Finding the right path among many standards.
Rajkumar SV
Hematol Oncol; 2021 Jun; 39 Suppl 1():68-72. PubMed ID: 34105809
[No Abstract] [Full Text] [Related]
58. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
59. Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
Kumar S; Williamson M; Ogbu U; Surinach A; Arndorfer S; Hong WJ
Cancer Med; 2021 Sep; 10(17):5866-5877. PubMed ID: 34402201
[TBL] [Abstract][Full Text] [Related]
60. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).
Ansell J; Hollowell J; Pengo V; Martinez-Brotons F; Caro J; Drouet L
J Thromb Thrombolysis; 2007 Apr; 23(2):83-91. PubMed ID: 17221328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
